Neuronal nicotinic acetylcholine receptors (nAChRs) both mediate direct cholinergic synaptic transmission and modulate synaptic transmission by other neurotransmitters. Novel ligands are needed as probes to discriminate among structurally related nAChR subtypes. ␣-Conotoxin MII, a selective ligand that discriminates among a variety of nAChR subtypes, fails to discriminate well between some subtypes containing the closely related ␣3 and ␣6 subunits. Structure-function analysis of ␣-conotoxin MII was performed in an attempt to generate analogs with preference for ␣6-containing [␣6* (asterisks indicate the possible presence of additional subunits)] nAChRs. Alanine substitution resulted in several analogs with decreased activity at ␣3* versus ␣6* nAChRs heterologously expressed in Xenopus laevis oocytes. From the initial analogs, a series of mutations with two alanine substitutions was synthesized. 125 I]␣-conotoxin MII binding to putative ␣6␤2* nAChRs in mouse brain homogenates (K i ϭ 3.3 nM). Thus, structure-function analysis of ␣-conotoxin MII enabled the creation of novel selective antagonists for discriminating among nAChRs containing ␣3 and ␣6 subunits.
nAChRs activated by the endogenous neurotransmitter acetylcholine belong to the superfamily of ligand-gated ion channels that also includes GABA A , 5-hydroxytryptamine-3, and glycine receptors (Changeux, 1993) . These different ligand-gated ion channels show considerable sequence and structural homology. Each of the subunits has a relatively hydrophilic amino terminal half (ϳ200 amino acids) that constitutes an extracellular domain. This is followed by three hydrophobic transmembrane domains, a large intracellular loop, and then a fourth hydrophobic transmembrane span.
A large number of genes have been cloned that encode subunits of nAChRs. It has been proposed that these subunits may be divided into subfamilies on the basis of both gene structure and mature protein sequence. The subunits ␣2, ␣3, ␣4, and ␣6 belong to subfamily III, tribe 1; ␤2 and ␤4 belong to tribe III-2; and the putative structural subunits ␣5 and ␤3 belong to tribe III-3 (Corringer et al., 2000) . Within tribe III-1, subunits ␣3 and ␣6 show considerable sequence identity (ϳ80% in the ligand-binding extracellular domain). Thus, designing ligands to distinguish between ␣3* 1 and ␣6* is particularly challenging.
␣-Conotoxin MII is a 16 amino acid peptide originally isolated from the venom of the marine snail Conus magus. This peptide potently targets neuronal in preference to the muscle subtype of nicotinic receptor with high affinity for both ␣3␤2 and ␣6* nAChRs. Unfortunately, ␣-conotoxin MII may not distinguish well between ␣3* and ␣6* nAChRs (Kuryatov et al., 2000) . In an effort to remedy this situation and produce a selective ligand for ␣6* nAChRs, we have generated a series of ␣-conotoxin MII analogs.
The ␣6 subunit is expressed in catecholaminergic neurons and in retina (Le Novère et al., 1996 Vailati et al., 1999) . In striatum, ␣6* nAChRs seem to play a central role in the modulation of dopamine release. Recently, homozygous null mutant (␣6Ϫ/Ϫ) mice were generated. Receptor autora-diography studies in these animals indicate that the ␣6 nAChR subunit is a critical component of [ 125 I]␣-conotoxin MII binding in the central nervous system (Champtiaux et al., 2002) . Studies using mice with nAChR subunit deletion indicate that ␣3 does not participate in most [
125 I]␣-conotoxin MII binding sites but does influence expression in the habenulo-peduncular tract (Whiteaker et al., 2002) . Thus, ␣6-selective ligands would be useful to distinguish the ␣6* majority form from the ␣3* minority of such sites.
Materials and Methods
Chemical Synthesis. Peptides were synthesized on a Rink amide resin, 0.45 mmol/g [Fmoc-Cys(Trityl)-Wang; Novabiochem, San Diego, CA] using N-(9-fluorenyl)methoxycarboxyl chemistry and standard side chain protection except on cysteine residues. Cysteine residues were protected in pairs with either S-trityl on the first and third cysteines or S-acetamidomethyl on the second and fourth cysteines. Amino acid derivatives were from Advanced Chemtech (Louisville, KY). The peptides were removed from the resin and precipitated, and a two-step oxidation protocol was used to selectively fold the peptides as described previously (Luo et al., 1999) . Briefly, the first disulfide bridge was closed by dripping the peptide into an equal volume of 20 mM potassium ferricyanide and 0.1 M Tris, pH 7.5. The solution was allowed to react for 30 min, and the monocyclic peptide was purified by reverse-phase HPLC. Simultaneous removal of the S-acetamidomethyl groups and closure of the second disulfide bridge was carried out by iodine oxidation. The monocyclic peptide and HPLC eluent was dripped into an equal volume of iodine (10 mM) in H 2 O/trifluoroacetic acid/acetonitrile (78:2:20 by volume) and allowed to react for 10 min. The reaction was terminated by the addition of ascorbic acid diluted 20-fold with 0.1% trifluoroacetic acid and the bicyclic product purified by HPLC.
Mass Spectrometry. Measurements were performed at the Salk Institute for Biological Studies (San Diego, CA) under the direction of Jean Rivier. Matrix-assisted laser desorption ionization time-offlight mass spectrometry and liquid secondary ionization mass spectrometry were used.
Preparation of nAChR Subunit cRNA. Attempts to express the rat nAChR ␣6 subtype in Xenopus laevis oocytes consistently failed; that is, no ACh-gated currents were detected. To improve functional expression, we created a chimeric receptor of the rat ␣6 and ␣3 subtypes. The chimeric receptor consists of amino acids 1 to 237 of the rat ␣6 subunit protein linked to amino acids 233 to 499 of the rat ␣3 subunit protein. The chimeric junction is located at the paired -RR-residues immediately preceding the M1 transmembrane segment of the ␣3 subunit. The resulting chimeric receptor represents the extracellular ligand-binding domain of the ␣6 subunit linked to membrane-spanning and intracellular segments of the ␣3 subunit. The ␣6/␣3 cDNA was constructed by the introduction of BspEI sites at the chimeric junction into the ␣6 and ␣3 cDNA sequences using mutagenic primers to introduce the restriction sites through silent codon changes. The ␣6 and ␣3 segments were generated by polymerase chain reaction of rat brain cDNA using primers in the 5Ј and 3Ј untranslated regions of the corresponding cDNAs along with the internal mutagenic primers. The polymerase chain reaction products were digested with BspEI and ligated to generate the chimeric construct. The final chimeric construct was cloned and completely sequenced to confirm the correct cDNA sequence. To further improve expression levels, all of the 5Ј and 3Ј untranslated regions of the nAChR cDNA were deleted, and the chimeric construct was cloned into the X. laevis expression vector pT7TS, placing X. laevis globin 5Ј and 3Ј untranslated regions around the nAChR cDNA. The expression construct pT7TS/r␣6␣3 was transcribed with T7 RNA polymerase to generate sense-strand RNA for oocyte expression.
Electrophysiology and Data Analysis. Clones of rat nAChR subunits were used to produce cRNA for injection into X. laevis oocytes as described previously (Cartier et al., 1996) . The rat ␣6 and ␤3 subunits were a generous gift from S. Heinemann (Salk Institute, San Diego, CA) (Deneris et al., 1989) . To express nAChRs in oocytes, 5 ng of each nAChR subunit was injected. In the case of ␣6␤4, 50 ng of each subunit was injected because of absent expression when using 5 ng of cRNA. Likewise, 20 ng was used for the ␣6/␣3␤2 combination that expresses poorly without the ␤3 subunit. A 30-l cylindrical oocyte recording chamber fabricated from Sylgard was gravity-perfused with ND96A (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl 2 , 1.0 mM MgCl 2 , 1 M atropine, and 5 mM HEPES, pH 7.1-7.5) at a rate of ϳ2 ml/min (Luo et al., 1998) . All toxin solutions also contained 0.1 mg/ml bovine serum albumin to reduce nonspecific adsorption of peptide. Toxin was preapplied for 5 min. ACh-gated currents were obtained with a 2-electrode voltage-clamp amplifier (model OC-725B; Warner Instrument, Hamden, CT), and data were captured as described previously (Luo et al., 1998) . The membrane potential of the oocytes was clamped at Ϫ70 mV. To apply a pulse of ACh to the oocytes, the perfusion fluid was switched to one containing ACh for 1 s. This was done automatically at intervals of 1 to 5 min. The shortest time interval was chosen such that reproducible control responses were obtained with no observable desensitization. The concentration of ACh was 10 M for trials with ␣1␤1␦⑀ and 100 M for all other nAChRs. Toxin was bath-applied for 5 min, followed by a pulse of ACh. Thereafter, toxin was washed away, and subsequent ACh pulses were given every 1 min, unless otherwise indicated. All ACh pulses contain no toxin, for it was assumed that little if any bound toxin washed away in the brief time (less than the 2 s it takes for the responses to peak). In our recording chamber, the bolus of ACh does not project directly at the oocyte but rather enters tangentially, swirls, and mixes with the bath solution. The volume of entering ACh is such that the toxin concentration remains at a level Ͼ50% of that originally in the bath until the ACh response has peaked (Ͻ2 s). When longer than 5 min of toxin application was needed to reach maximum block, toxin was applied by continuous perfusion to the oocytes as described previously (Luo et al., 1994) , except that ACh was applied once every 2 min.
The average peak amplitude of three control responses just preceding exposure to toxin was used to normalize the amplitude of each test response to obtain a "% response" or "% block". Each data point of a dose-response curve represents the average value Ϯ S.E. of measurements from at least three oocytes. Dose-response curves were fit to the equation %response ϭ 100/{1 ϩ ([toxin]/IC 50 ) nH }, where n H is the Hill slope determined with Prism software (GraphPad Software, San Diego, CA) on an Macintosh (Apple Computers, Cupertino, CA). For three or fewer data points, n H was set to 1.0.
Membrane Preparation. Mice were killed by cervical dislocation. Brains were removed from the skulls and dissected on an ice-cold platform. Membranes containing [
125 I]␣-conotoxin MII binding sites were prepared from pooled olfactory tubercles, striatum, and superior colliculus. Samples were homogenized in 2ϫ physiological buffer (288 mM NaCl; 3 mM KCl; 4 mM CaCl 2 ; 2 mM MgSO 4 ; and 40 mM HEPES, pH 7.5; 22°C) using a glass-polytetrafluoroethylene tissue grinder. Homogenates were then treated with phenylmethylsulfonyl fluoride (final concentration, 1 mM; 15 min at 22°C) to inactivate endogenous serine proteases before centrifugation (20,000g for 20 min at 4°C). Pellets were washed twice by homogenization in distilled deionized water glass-polytetrafluoroethylene tissue grinder, 4°C) and centrifugation (20,000g for 20 min at 4°C). Pooled tissue from a single mouse provided sufficient material for a single 96-well format assay.
Inhibition of [ 125 I]␣-Conotoxin MII Binding. Inhibition of [ 125 I]␣-conotoxin MII binding to mouse brain membranes was performed using a modified version of the 96-well plate procedure described previously (Whiteaker et al., 2000a) . Assays were performed in triplicate using 1.2-ml siliconized polypropylene tubes arranged in a 96-well format. Membrane pellets were resuspended into distilled ␣-Conotoxin MII Analogs Are Selective for ␣6* nAChRs deionized water. Total (no drug) and nonspecific (with 1 M epibatidine) binding determinations were included in each experiment for each drug dilution series. Initial incubations proceeded for 3 h at 22°C in 1ϫ protease inhibitor buffer [1ϫ physiological buffer supplemented with bovine serum albumin (0.1% w/v), 5 mM EDTA, 5 mM EGTA, and 10 g/ml each of aprotinin, leupeptin trifluoroacetate, and pepstatin A]. Each tube contained 10 l of membrane preparation, 10 l of competing ligand (or nonspecific or total determinations) in 1ϫ protease inhibitor buffer, and 10 l of [
125 I]␣-conotoxin MII (1.5 nM in 2ϫ protease inhibitor buffer, giving a final assay radioligand concentration of 0.5 nM). After incubation, each tube was diluted with 1 ml of physiological buffer plus 0.1% (w/v) bovine serum albumin. Tubes were then incubated for a further 4 min at 22°C to reduce nonspecific binding to the membrane preparation. The binding reactions were then terminated by filtration onto a single thickness of GF/F filter paper (Whatman, Clifton, NJ) using a cell harvester (Inotech Biosystems, Rockville, MD). The filters were incubated previously for 15 min with 5% dried skim milk to reduce nonspecific binding. Assays were washed with four changes of physiological buffer supplemented with bovine serum albumin (0.1% w/v). Washes were performed at 30-s intervals, with each lasting approximately 5 s. All filtration and collection steps were performed at 4°C. Bound ligand was quantified for each filter disc by gamma counting using a Cobra II counter (Ϸ85% efficiency) (PerkinElmer Life and Analytical Sciences, Boston, MA).
Calculations. Data from individual [ 125 I]␣-conotoxin MII inhibition binding experiments were processed using a single-site fit using the nonlinear least-squares fitting algorithm of GraphPad Prism. Values of K i were derived for each experiment by the method described by Cheng and Prusoff (1973) ,
Results
Peptide Synthesis. The sequence of native ␣-conotoxin MII is GCCSNPVCHLEHSNLC. Peptide analogs were synthesized by substituting one or more residues with alanine. These peptides are named according to the residue(s) substituted; for example, MII[E11A] has the glutamic acid in position 11 substituted with alanine. Cysteine residues were orthogonally protected to direct the formation of disulfide bonds in the configuration found in ␣-conotoxin MII, that is cysteine 1 to cysteine 3 and cysteine 2 to cysteine 4. The first and third cysteine residues were protected with acid-labile groups that were removed first after a cleavage from the resin; ferricyanide was used to close the first disulfide bridge. The monocyclic peptides were purified by reverse-phase HPLC. Then the acid-stable acetamidomethyl groups were removed from the second and fourth cysteines by iodine oxidation that also closed the second disulfide bridge. The fully folded peptides were again purified by HPLC. Mass spectrometry was used to confirm synthesis. The observed molecular mass for each peptide was within 0.1 Da of the expected mass.
Peptide Effects on ␣6* and ␣3* nAChRs. Injection of rat ␣6 subunits into oocytes either alone or in combination with ␤2 and/or ␤3 subunits yields few or no functional nAChRs. Using a previously reported strategy for human ␣6 (Kuryatov et al., 2000) , we joined the extracellular domain of the rat ␣6 subunit to the transmembrane and intracellular at ASPET Journals on August 27, 2017 molpharm.aspetjournals.org portion of the closely related rat ␣3 subunit. Alanine analogs were then tested against ␣3␤2 or ␣6/␣3␤2␤3 subunit combinations heterologously expressed in oocytes. The ␤3 subunit was used with ␣6/␣3␤2, for without it there was generally little or no functional expression. In addition, ␤3 is associated with native ␣6␤2*-containing nAChRs Cui et al., 2003) . Results are shown in Fig. 1 and Table 1 . Substitution of alanine for Asn5, Pro6, or His12 resulted in substantially decreased activity compared with native MII at both ␣6* and ␣3* nAChRs, whereas substitution for Val7 had the most pronounced effect on the ␣6/␣3␤2␤3 nAChR. Substitution for Ser4, His9, Leu10, Glu11, Ser13, Asn14, and Leu15 had only modest effects on ␣6/␣3␤2␤3; however, mutations at Ser4, His9, Glu11, Asn14, and Leu15 resulted in substantially lower activity on ␣3␤2 nAChRs. Thus, these mutations are analogs that preferentially block ␣6/␣3␤2␤3 versus ␣3␤2 nAChRs. We note that for certain analogs, including S4A, L10A, E11A, S13A, and N14A, the t 1/2 for recovery from toxin block of ␣6/␣3␤2␤3 nAChRs was long (Ͼ25 min). For these analogs, 10-to 15-min toxin incubations were used to achieve maximum block at 10 nM concentration, and 20-to 35-min incubations were used to achieve maximum block at 1 nM concentration. A slow off-rate but similar affinity to other analogs implies that the analogs with a slow off-rate also have slower on-rates and thus the need for longer application times. MII[H9A] and MII[L15A] failed to block ␣4␤2 nAChRs; at 10 M peptide concentration, the ACh-evoked current was 105.8 Ϯ 2.4 and 102.3 Ϯ 5.3% of control, respectively (data from six oocytes).
Selectivity of MII[E11A].
The single alanine substitution MII[E11A] has ϳ50-fold preference for ␣6/␣3␤2␤3 versus ␣3␤2 nAChRs and seems to be the most potent analog on ␣6/␣3␤2␤3 nAChRs. We therefore tested its effects on additional nAChR subtypes. The apparent on-rate for ␣6/␣3␤4 nAChRs is slow; at concentrations of toxin Յ 10 nM, 60 to 70 min of toxin application was required to reach a steady-state level of nAChR block. Concentration-response curves are shown in Fig. 2 and IC 50 values are shown in Table 2 . A series of double alanine-substituted mutations was also constructed. These mutations were tested with respect to their activity at ␣6/␣3␤2␤3 and ␣3␤2 nAChRs. As seen in Table 3 , each of these double mutants preferentially blocks the ␣6/␣3␤2␤3 receptor versus the ␣3␤2 receptor. The IC 50 of the MII[H9A;L15A] analog was approximately 2000-fold lower for ␣6/␣3␤2␤3 versus ␣3␤2, and this analog was selected for further characterization (Fig. 3) .
Kinetics of Block by MII[H9A;L15A]. ␣-Conotoxin MII is slowly reversible on ␣3␤2 nAChRs and very slowly reversible on ␣6/␣3␤2␤3 nAChRs (Fig. 4) . Substitution of Ala for His9 or Leu15 leads to more rapid recovery from block for both receptor subtypes. In the case of the double mutant MII[H9A;L15A] recovery from toxin block is rapid. The magnitude of the change of recovery rate is greater than the magnitude of change in IC 50 at the ␣6/␣3␤2␤3 receptor. This implies that changes in the peptide that lead to a rapid off-rate also lead to a faster on-rate of binding. We note that ␣-conotoxin GIC, a more rapidly reversible homolog of ␣-conotoxin MII, also has an alanine rather than the histidine found in position 9 of ␣-MII .
Activity of MII[H9A;L15A] on Other nAChR Subtypes. MII[H9A;L15A] has highest affinity for the ␣6/␣3␤2␤3 subunit combination and ϳ100-fold less activity on the ␣6/␣3␤4 combination (Fig. 3) . MII[H9A;L15A] has low or no activity on the remaining neuronal subunit combinations tested, including ␣2␤2, ␣2␤4, ␣3␤4, ␣4␤2, ␣4␤4, and ␣7 ( Fig. 5 and (Whiteaker et al., 2000b) to mouse brain homogenates. Results are shown in Fig. 6 . The values obtained for these analogs correlate well with values obtained on ␣6/␣3␤2␤3 rather than ␣3␤2 nAChRs as expressed in X. laevis oocytes (Table 5) .
Discussion
Although the sequence of the coding region for the ␣6 gene has been known for many years (Lamar et al., 1990) , its functional significance has been challenging to elucidate because of difficulties in heterologously expressing ␣6 and because of a lack of subtype-specific ligands. Indeed, originally it was not entirely certain that the ␣6 gene encoded a nicotinic receptor subunit. The ␣6 subunit has relatively discrete localization, with expression in catacholaminergic nuclei including the locus coeruleus, the ventral tegmental area, and the substantia nigra (Le Novère et al., 1996; Göldner et al., 1997; Han et al., 2000; Quik et al., 2000; Azam et al., 2002) . It is also found in trigeminal ganglion and olfactory bulb (Keiger and Walker, 2000) . In addition, ␣6 complexes have been reported in chick retina (Vailati et al., 1999) . The ␣6 mRNA expression pattern overlaps extensively with that of the ␣3 subunit, leading to initial confusion over the composition of [ 125 I]␣-conotoxin MII-binding nAChRs (Whiteaker et al., 2000b) .
Subunit-specific antibodies have been used to immunoprecipitate ␣6* receptors from chick retina. When reconstituted in lipid bilayers, these receptors formed cationic channels characteristic of nAChRs, thus establishing a functional role for native ␣6* nAChRs (Vailati et al., 1999) . Antibodies have also been used recently to demonstrate the presence of ␣6␤2* nAChRs in striatal dopaminergic terminals in rat. ␤3 and/or ␣4 subunits are also present in a proportion of these nAChRs . Subunit knockout mice suggest that the high-affinity binding site of [
125 I]␣-conotoxin MII is predominately composed of ␣6* rather than ␣3* nAChRs (Champtiaux et al., 2002; Whiteaker et al., 2002) . It has been hypothesized recently that putative ␣6* nAChRs in the striatum may participate in the pathophysiology of Parkinson's disease, a neurodegenerative disorder characterized by progressive loss of dopamine neurons. Treatment of primates with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (a dopaminergic neurotoxin) leads to selective decline of putative ␣6␤2* nAChRs (Quik et al., 2001; Kulak et al., 2002) . Thus, there is a significant need for ligands that selectively act at ␣6* nAChRs.
We demonstrate in this report that certain analogs of ␣-conotoxin MII exhibit preferential loss of activity at ␣3␤2 versus ␣6/␣3␤2␤3 nAChRs. Additionally, at concentrations tested, the MII[H9A;L15A] analog has little or no activity at ␣2*, ␣4*, or ␣7* nAChRs. Indeed, MII[H9A;L15A] is the most selective ␣6 ligand thus far reported.
A number of native ␣-conotoxins have been characterized that target various subtypes of nAChRs. Despite their differences in primary sequence, NMR and X-ray crystallography studies show a high conservation of the structural peptide backbone (Hu et al., 1996 (Hu et al., , 1997 (Hu et al., , 1998 Shon et al., 1997; Hill et al., 1998; Cho et al., 2000; Park et al., 2001; Nicke et al., 2003) . It seems that this backbone serves as a scaffold that presents a variety of amino acid side chains leading to differences in specificity. In the present study, we have systematically replaced the noncysteine residues of ␣-conotoxin MII with alanine. The predominant effect is to preferentially decrease activity at the ␣3␤2 receptor relative to the ␣6/ ␣3␤2(Ϯ␤3) subunit combination.
In an attempt to further increase selectivity, double mutations were constructed from the more selective single mutation analogs. Each of these double mutants retains a low nanomolar IC 50 for the ␣6/␣3␤2␤3 nAChR (Table 3) . It is particularly noteworthy that the native MII peptide potently blocks both ␣6/␣3␤2␤3 and ␣3␤2 nAChRs, whereas the MII[H9A;L15A] analog discriminates between these nAChRs by three orders of magnitude. This discrimination is caused by differences in the extracellular region of the ␣ subunit because the transmembrane and intracellular portions of the chimeric ␣6/␣3 and ␣3 subunits are identical. Also, the addition of the ␤3 subunit to ␣6/␣3␤2 nAChRs has only a 3.4-fold effect on MII[H9A,L15A] block. MII[E11A] also preferentially blocks ␣6/␣3␤2 versus ␣3␤2 nAChRs, again implicating the extracellular portion of the ␣6 subunit. Furthermore, coexpression of the ␤3 subunit with the ␣6/␣3 and ␤2 subunits had no effect on the IC 50 of MII [E11A] . However, the presence of a ␤2 versus ␤4 subunit does seem to influence peptide affinity. MII[E11A] preferentially blocks ␣6/␣3␤2 versus ␣6/␣3␤4 nAChRs and preferentially blocks ␣3␤2 versus ␣3␤4 nAChRs.
We used cloned rat receptor subunits heterologously expressed in X. laevis oocytes to examine the differences between ␣3* and ␣6* nAChRs. Although difficult, occasional expression of ␣6 with either ␤2 or ␤4 subunits has been described. This expression is enhanced with the addition of the ␤3 subunit (Kuryatov et al., 2000) . Improved efficiency of expression has been achieved by combining the extracellular (putative ligand binding) domain of ␣6 with the remaining portion of either the ␣3 or ␣4 subunit (Kuryatov et al., 2000) . We have exploited this technique to screen analogs of ␣-conotoxin MII. It is possible that there are important differences between this chimeric receptor expressed in oocytes and native nAChRs. To assess this, the ␣-conotoxin MII analogs were also tested in a radioligand binding assay using native nAChR populations. As can be seen in Table 5 , the analogs that potently block the rat ␣6/␣3␤2␤3 nAChR heterologously expressed in oocytes also potently block the native mouse striatal nAChR bound by radiolabeled MII. This native receptor has been shown in previous studies to contain ␣6 (rather than ␣3) and ␤2 subunits (Champtiaux et al., 2002; Whiteaker et al., 2002; Zoli et al., 2002) . Thus, the analogs have high affinity for both native and heterologously expressed ␣6␤2* nAChRs. The H9A;L15A analog of MII also has a relatively high IC 50 for other nAChRs, including ␣2␤2, ␣2␤4, ␣3␤2, ␣3␤4, ␣4␤2, ␣4␤4, and ␣7. Thus, this peptide represents a novel selective probe for discriminating among numerous nAChR subunit combinations.
The precise mechanism by which the [H9A] and [L15A] mutations cause a selective loss of affinity at ␣3␤2 relative to ␣6/␣3␤2* nAChRs is not addressed by these studies. It has been determined that Lys185 and Ile188 of the ␣3 subunit are critically important for ␣-conotoxin MII binding to ␣3␤2 nAChRs (Harvey et al., 1997) , and these residues are conserved between the ␣3 and ␣6 subunits. The most facile explanation of the results presented here is that the crucial interactions between ␣-conotoxin MII and the ␣6 subunit may occur at other subunit side chains. Interestingly, both ␣-conotoxin PnIA and ␣-conotoxin MII interact with Ile188 but differ in other important interactions with the ␣3 subunit. ␣3 subunit Lys185 is not essential to ␣-conotoxin PnIA binding, whereas Pro182 and Gln198 are (Everhart et al., 2003) . Perhaps significantly, the latter two residues are not conserved between the ␣3 and ␣6 subunit. Because all of the above residues are found in the putative "C" loop of the ␣ subunit, it seems possible that interaction in this region may be of particular importance. However, several examples indicate that a more complex explanation may be needed. For instance, ␣-conotoxin PnIA and its derivative ␣-conotoxin PnIA[A10L] stabilize different states of the same nAChR (Hogg et al., 2003) , presumably by interacting with different sets of subunit residues, whereas ␣-conotoxin MI has been shown to interact in a different orientation with the same ␣1 subunit residues, depending on whether it is binding at an ␣/␥ or ␣/␦ interface (Sugiyama et al., 1998) . These and a series of mutant-cycle analysis studies (Quiram et al., 1999 (Quiram et al., , 2000 Bren and Sine, 2000) have indicated that toxin/channel interactions may be anchored by a small number of relatively strong interactions and supported by a large number of weaker interactions that strongly determine subtype selectivity (Rogers et al., 2000) . If this more multifaceted model is correct, the maintenance of affinity between ␣-conotoxin MII[H9A;L15A] and the ␣6/␣3␤2* nAChR may reflect either a more prominent role of the "supporting" interactions with the native toxin than is seen for ␣3␤2, which is retained after alteration of the His9 and Leu15 side chains. Alternatively, the orientation of the toxin within the binding pocket may shift after substitution at the His9 and Leu15 positions, but the structure of the ␣6/␣3 binding pocket may be better able to accommodate the new positioning than its ␣3 counterpart. The fact that several of the alanine mutants exhibit affinities similar to each other and native ␣-conotoxin MII but have radically different binding kinetics reinforces the idea that different interactions may stabilize the nAChR/toxin complex in each case. It seems likely that an accurate understanding of how the [H9A] and [L15A] mutations produce selectivity between ␣3␤2 and ␣6/␣3␤2* nAChRs will require the performance of a comprehensive set of double mutant-cycle analyses. ␣-Conotoxin MII Analogs Are Selective for ␣6* nAChRs
